Related Experiment Video
Updated: May 1, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
[Treatment of Hodgkin lymphoma]
Abstract:
Hodgkin lymphoma became to be a curative disease. The standard treatment has been established for Hodgkin lymphoma, but its optimization still is explored. Risk stratification is critical in terms of optimization. The favorable patients would be treated with less toxic regimens. PET results are now used to evaluate the treatment response, and recently interim PET has been shown as a good predictor of prognosis. Interim PET is now incorporated into the treatment strategy of Hodgkin lymphoma in clinical trials. Molecular targeting drugs have been developed. Brentuximab vedotin, a kind of antibody drug conjugate, showed favorable clinical results for relapsed Hodgkin lymphoma.
More Related Videos
08:53Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Treatment Resistent Cancers